Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2025
0mins
Source: Globenewswire
FDA Meeting and NDA Submission: Cingulate Inc. has scheduled an in-person Pre-NDA meeting with the FDA on April 2, 2025, and is targeting a new drug application submission for its ADHD treatment CTx-1301 by mid-2025, following positive safety results from Phase 3 trials.
Financial Update: The company reported a $17.5 million increase in working capital, extending its cash runway into Q4 2025, and highlighted a significant reduction in net loss from $23.5 million in 2023 to $15.5 million in 2024, reflecting improved financial health and completed clinical activities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
